Pfizer Inc (PFE)
Deutsche Börse Xetra · Germany · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 26.65 |
|---|---|
| 52-week range | 20.72 – 27.12 |
| Return, 1 month / 3 months | +7.4% / +22.1% |
| Return, 1 year / 3 years | +34.5% / +13.8% |
| Trend | Uptrend |
| RSI (14) | 62 |
| Volatility (1 year) | 22.1% |
| Worst drawdown (1 year) | -14.5% |
| Average daily value traded | 0.88M EUR |
| Dividend yield | 5.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Pfizer Inc is a pharmaceutical company that researches, develops and makes prescription medicines and vaccines. Its products address areas such as infectious disease, oncology, immunology and internal medicine, and include vaccines and antiviral treatments. Customers are mainly hospitals, clinics, physicians, pharmacies and health systems, along with government health bodies that run immunisation programmes. The company is based in New York City in the United States and supplies medicines to markets around the world.
The shares are listed on the Deutsche Börse Xetra in Germany under the code PFE, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Pfizer Inc (PFE) trades on the Deutsche Börse Xetra in Germany. It last closed at EUR 26.65 on 27 October 2026.
Its price-based Market X-Ray is 84 out of 100 (a strong price profile), ranking 7 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 34.5% and over the last three months it rose 22.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Deutsche Börse Xetra
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 87 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 17.4% | ||
| From 52-week high | -1.5% | ||
| Momentum | 82 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 22.1% | ||
| 6-month return | 20.0% | ||
| 12-month return, skipping the last month | 25.2% | ||
| Stability (higher is calmer) | 91 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 22.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -14.5% | ||
| Liquidity | 70 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.88M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 87 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 5.1% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −0.6% |
|---|---|
| 1 month | +7.4% |
| 3 months | +22.1% |
| 6 months | +20.0% |
| 1 year | +34.5% |
| 3 years | +13.8% |
| 5 years | −5.4% |
Signals
| 50-day / 200-day average | 24.89 / 22.70 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.47 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Jul 2026 | USD 0.3825 |
| 8 May 2026 | USD 0.3825 |
| 23 Jan 2026 | USD 0.3825 |
| 7 Nov 2025 | USD 0.3825 |
| 25 Jul 2025 | USD 0.3825 |
| 9 May 2025 | USD 0.3825 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Deutsche Börse Xetra; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.